SCHEMBL4235345

SCHEMBL4235345

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(N(CCOC)C(=O)c3ccc(OC4CCNCC4)cc3)cc2)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
MCHR1 Q99705 7/20 0.38
KDM1A O60341 1/20 0.36
MEN1 O00255 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
HTT P42858 1/20 0.35
TOP2A P11388 1/20 0.35
FGFR1 P11362 1/20 0.35
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
POLB P06746 1/20 0.34
MLNR O43193 1/20 0.33
QPCT Q16769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233925 0.94 PKM (0.39) PKMTAS1R3TAS1R1MCHR1KDM1A
SCHEMBL4238039 0.91 PKM (0.39) PKMTAS1R3TAS1R1MCHR1KDM1A
SCHEMBL13699242 0.90 PKM (0.37) PKMTAS1R3TAS1R1MCHR1MEN1
SCHEMBL4745445 0.90 MCHR1 (0.38) PKMTAS1R3TAS1R1MCHR1MAPT
SCHEMBL4228512 0.88 SMN1; SMN2 (0.41) PKMTAS1R3TAS1R1MCHR1MEN1
SCHEMBL4686644 0.87 MEN1 (0.40) MCHR1MEN1GAAMAPTKMT2A
SCHEMBL4237954 0.87 SMN1; SMN2 (0.39) PKMTAS1R3TAS1R1MCHR1KMT2A
SCHEMBL4236654 0.86 PKM (0.47) PKMTAS1R3TAS1R1MCHR1MEN1
SCHEMBL4229108 0.86 MCHR1 (0.36) PKMTAS1R3TAS1R1MCHR1KMT2A
SCHEMBL4226836 0.84 SMN1; SMN2 (0.41) PKMTAS1R3TAS1R1MCHR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.